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Abstract
Background: Osteoporosis is a systemic metabolic disease based on age-dependent imbalance between the rates
of bone formation and bone resorption. Recent studies on the pathogenesis of this disease identified that bone
remodelling impairment, at the base of osteoporotic bone fragility, could be related to protein glycation, in
association to oxidative stress. The glycation reactions lead to the generation of glycation end products (AGEs)
which, in turn, accumulates into bone, where they binds to the receptor for AGE (RAGE). The aim of this study is to
investigate the potential role of circulating sRAGE in osteoporosis, in particular evaluating the correlation of sRAGE
with the fracture risk, in association with bone mineral density, the fracture risk marker FGF23, and lipid metabolism.
Results: Circulating level of soluble RAGE correlate with osteopenia and osteoporosis level. Serum sRAGE resulted
clearly associated on the one hand to bone fragility and, on the other hand, with BMI and leptin. sRAGE is
particularly informative because serum sRAGE is able to provide, as a single marker, information about both the
aspects of osteoporotic disease, represented by bone fragility and lipid metabolism.
Conclusions: The measure serum level of sRAGE could have a potential diagnostic role in the monitoring of
osteoporosis progression, in particular in the evaluation of fracture risk, starting from the prevention and screening
stage, to the osteopenic level to osteoporosis.
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Background
Osteoporosis is defined, according to 2001 NHI consen-
sus conference, as a systemic disease characterized by
loss of bone volume and resulting in a reduced skeletal
integrity leading to a higher risk of bone fracture [1, 2].
Osteoporosis develops because of an age-dependent im-
balance between the rates of bone formation and bone
resorption [3] and is an emerging disease due to the in-
crease of the population average age and its socioeco-
nomic and public health impact is estimated to
significantly increase in the next future. Due to the
association with bone fragility and fracture risk, this dis-
ease interferes not only with the quality of life but also
with life expectancy, in particular in elder people [4, 5] .
The current recommendation for osteoporosis screening
is the diagnosis by Bone Densitometry or DXA (Dual-
energy X-ray absorptiometry) Scan, but even though this
approach correlates with fracture risk and it can consid-
ered a good fracture predictor, many additional factors
play a role in determining risk of fracture. While the first
diagnosis of osteoporosis is based on bone mineral
density (BMD), the evaluation of the individual frac-
ture risk should consider all the clinical risk factors,
ranging from age, sex, metabolic status and bone re-
modelling status [6, 7].
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On the one hand, DXA scan gives the static measure-
ment of bone density in specific bone sites, on the other
hand, additional diagnostic tool, such as bone turnover
biomarkers, reflects the dynamic changes of bone turn-
over in the whole skeletal [8–10]. Therefore, the com-
prehension of the biochemical mechanisms involved in
the pathogenesis of osteoporosis could provide new
diagnostic tool for improving the sensibility and specifi-
city the prediction of fracture risk [7].
Osteoporosis is a systemic metabolic disease and re-
cent studies on the pathogenesis of this disease identi-
fied that bone remodelling impairment, at the base of
osteoporotic bone fragility, could be related to protein
glycation, in association to oxidative stress [5]. The gly-
cation reactions lead to the generation of glycation end
products (AGEs) which, in turn, accumulates into bone,
where they binds to the receptor for AGE (RAGE) [11].
The RAGE receptor belongs to the immunoglobulin
superfamily of cell- surface molecules expressed in dif-
ferent cell types, including osteoclasts and osteoblasts.
Upon binding AGEs, RAGE increase osteoclasts activity
and decrease osteoblasts activity [12, 13], thus con-
tributing to increase bone resorption and, ultimately,
bone fragility [5, 14].
The negative action of AGEs-RAGE axis is compen-
sated by the soluble form of RAGE receptor (sRAGE),
which is a decoy receptor of AGEs . Being a soluble
receptor, sRAGE binds AGEs but doesn’t lead to any sig-
naling pathway, thus competing with the signaling, cell-
bound RAGE receptor and, as a consequence, limiting
the AGEs-RAGE axis action [15].
RAGE may be bound by many ligands which include
advanced glycation endproducts (AGEs), certain mem-
bers of the S100/calgranulin family, extracellular HMGB1-
amphoterin, the integrin Mac-1, amyloid beta-peptide and
amyloid fibrils. Acting as counter-receptor for leukocyte
integrins RAGE may also have an important role in cell
adhesion and clustering as well as recruitment of inflam-
matory cells [16, 17]. Other important ligands for RAGE
may be glycosaminoglycans (including chondroitin sulfate,
dermatan sulfate and heparan sulfate) which are fre-
quently attached to proteoglycans on the surface of cancer
cells and play an important role in the malignant trans-
formation of the tumor and metastasis [17].
Being involved in the inflammatory response [18],
RAGE ligand (s)/RAGE system, in particular the axes
AGE-RAGE is involved in the pathogenesis of a variety
of inflammatory disorders, ranging from diabetes to
renal disease, sepsis and cardiovascular disease [11]. In
particular, the circulating soluble form of the RAGE re-
ceptor (sRAGE) has been recently described as a marker
of disease in different pathologies, ranging from cardio-
vascular disease to acute liver failure [19] and metabolic
disorder in obesity and diabetes [5, 20], but the
diagnostic role of sRAGE in osteoporosis has not been
described so far.
The aim of this study is to investigate the potential
role of circulating sRAGE in osteoporosis, in particular
evaluating the correlation of sRAGE with the fracture
risk, in association with bone mineral density e and the
fracture risk marker FGF23 (Fibroblast Growth Factor
23), involved in bone mineral metabolism. Since osteo-
porosis pathogenesis is strictly related with the meta-
bolic status [21, 22], the aim of this study is also to
evaluate the role of sRAGE as marker of osteoporosis in




The study involves 84 postmenopausal female volunteers
(mean age 53 ± 6 years old) enrolled in the region of
Lombardia and Calabria, as described in our previous
work (Montalcini et al. 2015 [23]). All participants were
evaluated for familiarity of osteoporosis and past frac-
tures, medication use, physical exercise and smoke
habits. Post menopausal status was defined as FSH level
higher than 40 IU/l or one year at least of absence of
natural mense.
Exclusion criteria were: presence of diabetes or any
metabolic condition affecting bone metabolism (kidney,
thyroid, rheumatic and hematological disease, malignant
tumors) taking drug, hormone therapy or vitamin D af-
fecting bone metabolism. The patients in our study was
not under bisphosphonates therapy or other anti-
osteoporotic therapy.
Written informed consent was obtained from all par-
ticipants included in the study. All procedures followed
were in accordance with the Helsinki of Declaration of
1975, as revised in 2000 and 2008 and it was approved
by both the Ethic Committee ASL Milan 2 and The
University Hospital Mater Domini, Catanzaro (Italy).
Trial registration number: 2631, name of registry: Comi-
tato Etico indipendente della ASL Milano due. URL:
http://www.aslm2.it, date of registration: September 19,
2011. Date of enrolment of the first participant 1 October
2011.
DXA assessment
BMD evaluation of lumbar spine and left femoral was
assessed by DXA (Horologic QDR Inc., MA. USA).
BMD was expressed as T -score (number of standard
deviation from healthy young mean) and Z- score
(number of standard deviations from healthy women of
the same age) calculated on the basis of physiological
reference values. On the basis of T-score value the pa-
tients was classified as having normal bone (T-
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score > −1), osteopenia (Tscore: −1 to −2.49) or osteo-
porosis (T-score ≤ − 2.5).
In vivo precision, calculated as repeated measurements
on 30 women, was <1%.
Anthropometric measurement
Body weight and BMI was measured as described in
Montalcini et al. 2015 [23]. Briefly, body weight was
measured with a calibrated scale before breakfast sub-
tracting the weight of clothes. Height was measured by
wall- mounted stadiometer and BMI was calculated as
weight (kg)/(height (m)) 2. According to BMI values, pa-
tients were classified as obese (BMI > 30), overweight
(BMI 25–30) or normal weight (BMI < 25).
Glomerular filtration rate
Glomerular filtration rate was calculated for the whole
population and for each RAGE quartile by CKD-EPI
formula:
GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 *
0.993Age * 1.018 [if female] * 1.159 [if black]Scr is serum
creatinine (mg/dL), κ is 0.7 for females and 0.9 for
males, α is −0.329 for females and −0.411 for males, min
indicates the minimum of Scr/κ or 1, and max indicates
the maximum of Scr/κ or 1.
sRAGE, FGF23 and adipokines ELISA assay
Blood was sampled from all patients and sera were sepa-
rated from whole blood after complete coagulation, by
centrifugation at 3000 rpm for 10 min. Sera were stored
at −70 °C until ELISA assay analyses.
Levels of soluble RAGE, C-Terminal FGF23, Leptin,
Adiponectin and Visfatin in serum were determined by
commercial assays, according to the manufacturers’
instructions (sRAGE: R&D Systems, Minneapolis,
Minnesota, USA; C-Terminal FGF23: Imuunotopiscs,
San Clemente, CA, USA; Leptin: Enzo Life Sciences,
Farmingdale, New York, USA; Adiponectin and Visfatin:
AdipoGen AG, Liestal, Switzerland).
For the sRAGE assay, the sensitivity was 4.44 pg/mL,
and intra- and inter-assay coefficients of variation were
2.4% and 4.7%, respectively. For the FGF23 assay, the
sensitivity was 1.5 RU /mL, and intra- and inter-assay
coefficients of variation were2.4% and 4.7%, respectively.
According to manufacturer (, Imuunotopiscs, San Clem-
ente, CA, USA) 1RU roughly equates to 2 pg/mL. For
the Leptin assay, the sensitivity was 23.4. pg/mL, and
intra- and inter-assay coefficients of variation were 4.4%
and 3.7%, respectively. For the Adiponectin assay, the
sensitivity was 1 ng/mL, and intra- and inter-assay coef-
ficients of variation were 3.3% and 2.75%, respectively.
For the Visfatin assay, the sensitivity was 30.0 pg/mL,
and intra- and inter-assay coefficients of variation were
2.3% and 4.6%, respectively.
Statistical analysis
For all parameters, the normality of distribution of the
three groups was verified by KS (Kolmogorov-Smirnov)
normality and results are reported as mean ± standard
deviation (SD). Statistical analysis was done using one-
way ANOVA, p < 0.05 being considered significant and
p < 0.001 highly significant. The correlation of sRAGE
with LBMD (lumbar bone mineral density) and FBMD
(femoral bone mineral density) (expressed as T-score
and Z-score) and with FGF23 was calculated as Spearman
correlation (r) calculating the 95% confidence interval.
All statistical analysis was performed using PRISM 3.0
software.
Results
Glomerular filtration rate and sRAGE
Glomerular filtration rate was calculated by CKD-EPI
formula for the whole population and for each RAGE
quartile, in order to evaluate whether it could affect
sRAGE levels in our patients . The mean eGFR calculated
on the whole patient group was 88,71 ± 11,86 mL/min per
1.73 m2, while it resulted 85,05 ± 10,74, 89,45 ± 12,71,
88,91 ± 9,56, 84,85 ± 9,13 mL/min per 1.73 m2 in the first,
second, third and fourth sRAGE quartiles, respectively.
Therefore, no significative differences in eGFR were ob-
served among sRAGe quartiles and compared to total
mean eGFR.
sRAGE and bone mineral density
A total of 12 subject present osteoporosis, while 32 had
osteopenia and 40 normal bone density values, as
assessed by T-score and Z- score.
The serum level of circulating s RAGE was mea-
sured in the three groups of patients (osteopenic,
osteoporotic and normal bone, according to T-score
values). sRAGE displays a significative increase in
osteopenic patients (940.36 ± 206.79 pg/mL) and an
even more significative increase in osteoporotic pa-
tients (1028,54 ± 223.83 pg/mL) compared to patients
with normal bone (743.02 ± 204.91 pg/mL), (Fig. 1,
panel a). The population was divided according to
sRAGE quartiles, calculating in each quartiles the
mean lumbar and femoral T-score and Z-score values
(Fig. 1, panel b) and the amount of patients having
osteopenia, osteoporosis and normal bone according
to LMBD and FBMD T-score and T-score values
ranges (Fig. 1 panel c and d, respectively). The first
quartiles of sRAGE present no pathological T-score or
Z-score, the second and third quartile present osteo-
penia according to T-score but normal bone according
to Z-score, while the fourth quartile present a more
severe osteopenia according to both T-score and Z-
score mean value.. The first quartile of sRAGE showed
the highest percentage of patients with normal bone
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Fig. 1 (See legend on next page.)
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and the lower percentage of osteopenia and osteopor-
osis according to lumbar T-score (Fig. 1, panel c and
d). More significantly, classification based on Femoral
T-score (panel D) not only confirmed the percentage
of normal and osteopenic patients, but resulted in no
cases of osteoporosis in the lowest quartile of sRAGE.
The second, third and fourth quartile of sRAGE dis-
play very similar classification, having higher percent-
age of osteopenic patient and a lower percentage of
normal bone compared to the first quartile. More
interestingly, while osteoporotic percentage is nearly
constant in the three upper quartiles according to
femoral T-score, lumbar T-score classification under-
lined a little increase of osteoporosis percentage in the
fourth quartile of sRAGE. These results indicates in-
crease of osteoporosis percentage according to sRAGE
levels.
sRAGE and fracture risk
There is significative trend of increase of FGF23 accord-
ing to bone defect classification (Fig. 2 panel a) and
sRAGE quartiles (panel B), in particular the first quartile
displaying the lowest FGF23 value, below the cutoff of
fracture risk in the first quartile and reaching the highest
and very significative value in the highest quartile of
sRAGE.
The Spearman correlation analysis (Panel C) did not
find a strong correlation between serum FGF23 and the
whole sRAGE values, while after the classification into
sRAGE quartile an increasing correlation with serum
FGF23 emerged, reaching high value in the third and
even more in the fourth sRAGE quartile. These results
indicates a correlation between sRAGE and fracture
risck marker FGF23.
sRAGE and BMI
The categorization into sRAGE quartiles was applied to
analyze the metabolic status of the patients, evaluated by
BMI calculation. There is a trend, even if not statistically
significative, of decrease of BMI according to the in-
crease of sRAGE (Fig. 3 panel a). In order to analyze this
result in detail, we calculated the number of patients in
each sRAGE quartile having normal (<25), overweight
(25–30) or obese (>30) BMI (Fig. 3 panel b). According
to sRAGE quartiles, there is a trend of decrease of obes-
ity (BMI >30), reaching in the fourth sRAGE quartile the
complete absence of obese subject and a very high
prevalence of subjects with normal BMI. These results
indicates a trend of decrease of obesity according to
sRAGE levels.
BMI and bone status
Figure 4 Panel a shows the mean FMBD and LBMD as
Tscore and Z-score in three BMI group: normal
(BMI < 25), overweight (BMI: 25–30) or obese
(BMI > 30).Only in normal BMI group the mean lum-
bar T-score and femoral Z-score revealed a decrease
of BMD but since the BMD values of the group are
quite heterogeneous, Standard Deviation resulting in
quite high. The percentage of normal bone, osteopenic
and osteoporotic subject, according to lumbar (panel
B) and femoral (panel C) T-score values, was evaluated
into each BMI group. At the increase of BMI corres-
pond a decrease of osteopenia and osteoporosis, and
an increase of normal bone. In particular, according to
femoral T-score, at BMI values over 30 there is a
complete absence of osteoporotic subjects. These re-
sults indicates a decrease of osteopenia and osteopor-
osis according to BMI. Increase
sRAGE and Adipokines
Adiponectin and Visfatin (Fig. 5 panel a and b) displayed
no significative differences among sRAGE quartiles, while
Leptin and, as a consequence, Leptin/Adiponectin Ratio
(Fig. 5 panel c and d) displayed a statistically significative
decrease according to sRAGE quartiles.
Adiponectin and Visfatin display no significative cor-
relation with total sRAGE or sRAGE quartiles, while
Leptin and Leptin/Adiponectin Ratio displayed a good
negative correlation (p < 0.001) with total sRAGE. This
negative correlation increase according to sRAGE quar-
tiles and it is particularly evident and significative
(p < 0.001) n the forth quartile of sRAGE (panel E).
These results indicates a negative correlation of sRAGE
with leptin and Adiponectin.
Discussion
Several evidences indicated that AGEs are involved in
the pathogenesis of osteoporosis [5] and AGEs-RAGE
interaction modulates osteoclasts and osteoblasts activity
[24, 25]. For this reason we aimed to investigate the po-
tential diagnostic role of soluble RAGE in osteoporosis.
Our result clearly indicates that circulating level of sol-
uble RAGE correlate with osteopenia and osteoporosis
level (Fig. 1). This correlation is particularly evident by
scoring RAGE into four quartiles.. These results clearly
(See figure on previous page.)
Fig. 1 Serum sRAGE and bone density. Panel a: serum sRAGE (pg/mL) in patients displaying normal bone, osteopenia and osteoporosis, according to
Bone Mineral Density valuesPanel b bone mineral density, expressed as lumbar and femoral T- and Z-score, according to sRAGE quartiles Panel c and
d: percentage of patients in each sRAGE quartiles displaying normal bone, osteopenia and osteoporosis, according to Bone Mineral Density values,
expressed as lumbar T-score (panel c), and femoral T-score (panel d)
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indicate that sRAGE correlates with disease progression
from osteopenic to osteoporosis level. Usually sRAGE is
reported to be high in healthy patients and lower in
pathological condition, but this is not the first case
where sRAGE, on the contrary, correlates with disease
progression, behaving as a marker of disease progres-
sion. Indeed very recent evidenced that sRAGE, as
widely described by Kailash Prasad [26], is not always a
marker of good prognosis, because it can be reduced in
some disease [27–30] and elevated in others [30–33].
The biological function of sRAGE is to bind circulating
AGE, which could have detrimental effect on tissues,
thus playing a protective role. For this reason in most of
the cases, such as cardiovascular disorders, sRAGE, as a
protective factor, is elevated in healthy subject and low
in disease. On the contrary, in some cases such as dia-
betes renal disease, sRAGE is elevated compared to
healthy controls as well as AGEs [5]. Similarly, recent
evidences indicates a high level of sRAGE is present in
acute respiratory distress and bronchiolitis [34], idio-
pathic pulmonary fibrosis [35] and it can correlate with
disease severity in lung transplantation [35] and long
term hemodyalisis patients [36].
It is known that AGEs accumulates in bone tissue at in-
creasing ages, because bone tissue is susceptible to aGE ac-
cumulation due to its turnover. During bone remodelling
bone cells are in close proximity to to AGE-modified pro-
teins, such as collagen Type I and its degradation products.
Bone cells express RAGE and can directly interact with
Age, regulating differentiation maturation and function.
Fig. 2 sRAGE and FGF23. Panel a serum FGF23 (pg/mL) in patients displaying normal bone, osteopenia and osteoporosis, according to Bone
Mineral Density values Panel b serum FGF23 (pg/mL) in each sRAGE quartiles Panel c Spearman Correlation of serum FGF23 (pg/mL) with sRAGE
as total level and sRAGE quartiles
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Therefore, protein glycation in clearly involved in age-
regulating bone disorders [37]. Franke et al. reported that
on the one hand AGE-RAGE binding activates inflamma-
tory response by inducing NFkB and TNF-α, on the other
hand NFkB upregulates RAGE expression, thereby activat-
ing a self-promoting cicle among RAGE, Age and inflam-
matory mediators [37]. AGEs induced a decrease of
osteoblast proliferation and osteoblast apoptosis [38]. In
addition circulating AGE are reported to decrease bone
strength [39]. The circulating sRAGE is the direct effect of
the proteolitic cleavage of RAGE by metalloproteinases,
and recent evidences suggested that diseases characterized
by high level of MMPs, such as diabetes and renal disease
[40, 41] display high level of serum sRAGE compared to
healthy controls. Osteoporosis is characterized by a high
expression of MMPs, acting on bone matrix resorption,
and this can be the reason of high level of serum sRAGE
in osteoporosis level. Therefore, circulating levels of
sRAGE can be considered a direct indicator of circulating
AGEs and, therefore, bone resorption status.
Consistently with this, our data indicates that serum
sRAGE correlates with bone density decrease, ranging
from the level of osteopenia to marked osteoporosis,
confirming a correlation of serum sRAGE with the stage
of bone fragility. This is also confirmed by the correl-
ation of sRAGE quartiles with a strong marker of bone
fracture risk, FGF23, as shown in Fig. 2. Being an im-
portant regulator of vitamin D and phosphorus, a key
process in bone matrix turnover, Fibroblast growth
factor-23 (FGF23) is considered a strong marker of bone
fracture [42, 43]. In our patients there if we consider the
whole population there is not a strong correlation of
Fig. 3 sRAGE and BMI. Panel a BMI (mean ± SD) in patients in each sRAGE quartiles Panel b BMI classification (<25 normal weight, 25–30
overweight, >30 obese) in each sRAGE quartiles serum FGF23 (pg/mL) in each sRAGE quartiles
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FGF23 and total fracture risk, as reported by Montalcini
et Al, 2015 [23]. If we consider the classification accord-
ing to T-score into normal bone, osteopenic and osteo-
porotic patients, a slightly increasing concentration of
FGF23 results in osteopenic and osteoporotic group. In
particular the only significative difference is observed in
osteoporotic patients, displaying higher bone fragility,
while at the level of osteopenia the risk of fracture is still
too low to induce a marked and significative increase of
FGF23. In consistence with that, there is a strong signifi-
cative increase of FGF23 according to sRAGE quartiles,
with a significative increase in particular in the third and
even more in the highest quartile of sRAGE, suggesting
a correlation of sRAGE with the increasing risk of bone
fracture. This is also confirmed by the correlation analysis
between serum FGF23 and sRAGE quartiles: even if the
correlation with total sRAGE is not so strong, considering
sRAGE quartiles classification a strong positive correlation
emerges in the third and fourth quartiles. All these results
clearly indicate that sRAGE can be considered a new bio-
marker of fracture risk in the osteoporosis.
It is well established that bone fracture risk is influ-
enced not only by bone density but also by several meta-
bolic factors, such as BMI and lipid metabolism [21, 22].
Fig. 4 BMI and bone status. Panel a Bone Mineral Density values, expressed as lumbar and femoral T-and Z. core, according to BMI classification
(<25 normal weight, 25–30 overweight, >30 obese). Panel b and c percentage of patients displaying normal bone, osteopenia and osteoporosis,
according to Bone Mineral Density values lumbar Tscore (panel b) and femoral T score (panel c), in BMI groups (<25 normal weight, 25–30
overweight, >30 obese)
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For this reason, we evaluated the association of BMI
with the level of serum sRAGE. We observed a decrease
of BMI according to sRAGE quartiles, and in particular
if we categorize the patients into each sRAGE quartile
according to the BMI standard classification (BMI < 25:
normal weight, BMI 25–30 overweight, BMI > 30 obese)
we observe a sticking prevalence of normal weight sub-
ject in the highest quartile of sRAGE. Accordingly, no
obese subject is present in the highest quartile of sRAGE
while the highest prevalence of obese subject results in
the lowest quartile of sRAGE. This data indicate that
there is a negative correlation with sRAGE and BMI.
In order to evaluate the relationship between BMI and
bone status in our patients, we analyzed bone density
score (lumbar and femora T-and Z-score) in the three
BMI categories, as shown in Fig. 4. This result indicate
that a lower bone density correspond to a lower BMI.
This could appear contradictory, because, since BMI and
lipid metabolism influences bone turnover, it could be
supposed that elevated BMI and lipid metabolism cor-
respond to a low bone density. However, it is well estab-
lished that in obese patients there a counterbalancing
mechanism: high body weight requires a stronger bone
and, therefore, a higher bone density. Therefore, high
Fig. 5 sRAGE and adipokines. Panel a Adiponectin (ng/mL) in patients in each sRAGE quartiles. Panel b Visfatin (ng/mL) in patients in each sRAGE
quartiles. Panel c Leptin (ng/mL) in patients in each sRAGE quartile. Panel d Leptin /Adiponectin ratio in patients in each sRAGE quartiles. Panel
e correlation (Spearmann) between Adipokines and sRAGE
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BMI level, as confirmed in our patients, correspond to a
higher bone density. This result on the one hand con-
firmed the positive correlation between BMI and bone
density already reported in literature [44–46], on the
other hand, given the negative correlation between
sRAGE and BMI, confirm the role of sRAGE as a
marker of bone fragility and fracture risk. In order to
deeply correlate the relationship between s RAGE and
lipid metabolism me evaluated a panel of the main adi-
pokine (adiponectin, visfatin and leptin) and correlated
them to serum sRAGE. According to s RAGE quartile,
no significative differences are observed for Adiponectin
and Visfatin. These results confirm previous evidences
indicating that adiponectin and visfatin are controversial
in osteoporotic patient s and cannot be considered good
markers of osteoporosis [47, 48]. On the contrary, leptin
displayed a statistically significative decrease into sRAGE
quartiles, in accordance with BMI data. In addition to
the single adipokines, the leptin/adiponectin ratio (LAR)
is usually used to analyzed the lipid metabolism [49] and
in our patients LAR displays the same trend of decrease,
with significative lower level in the highest sRAGE quar-
tile. This result are confirmed by correlation analysis, indi-
cating that leptin and leptin/adiponectin ratio display a
strong correlation with sRAGE, both as total sRAGE and
into quartiles, in particular in the highest sRAGE quartile.
Taken together these results indicates that s RAGE
display a strong negative correlation with leptin and
LAR ratio.
This is the first study to our knowledge evaluating
serum sRAGE in normal, osteopenic and osteoporotic
patients. The limit of the study is to evaluate only few of
the great number of parameter in the global evaluation
of bone and lipid metabolism in fracture risk. This is
pilot study evaluating the association of sRAGE and
bone fragility in osteoporosis, and further investigation
could be performed on a wider panel of parameter. The
study is performed on a selected population of a small
number of patients, all belonging to female gender and re-
cruited into a local area, but since osteoporosis affects also
male, further investigation could be performed on both
genders, in order to replicate and extend the analysis.
This marker resulted clearly associated on the one
hand to bone fragility and, on the other hand, with BMI
and leptin. Since the ultimate goal of osteoporosis diag-
nosis and monitoring is the evaluation of fracture risk, it
is important to take into account all the aspect affecting
bone fragility. In this context sRAGE is particularly in-
formative because serum sRAGE is able to provide, as a
single marker, information about both the aspects of
osteoporotic disease, represented by bone fragility and
lipid metabolism.
The exact mechanism connecting AGEs and bone fra-
gility is still unclear, but the level of advanced glycation
end products (AGEs) have been recently reported to be
inversely correlated with bone toughness and rigidity, due
to their role in the inhibition of the synthesis of type I col-
lagen, [39, 50, 51]. In addition, it is known that obesity is
connected with increased amounts of AGE in the body
[52, 53], leading to decreased bone toughness. In this con-
text, our results shows that sRAGE would play a role in
regulating AGEs, also according to lipid metabolism.
Conclusion
The measure serum level of sRAGE could have a poten-
tial diagnostic role in the monitoring of osteoporosis
progression, in particular in the evaluation of fracture
risk, starting from the prevention and screening stage, to
the osteopenic level to osteoporosis.
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